Saturday 17 October 2026
Export SNOA’s income statement to Excel — free account
Sonoma Pharmaceuticals, Inc.
SNOA Healthcare Drug Manufacturers Specialty & Generic
Sonoma Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $19.5 million, up 36.7% from fiscal 2025. In the quarter to June 2026, revenue grew 59.6%, EPS grew 88.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.
1.13
0.02
−1.74%
Follow SNOA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.38 | 0.35 | 0.18 | 0.22 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.06) | (8.16) | (6.91) | (7.29) | |
P/B ratio |
1.69 | 1.82 | 1.16 | 0.72 | |
Price to Tangible BV |
1.69 | 1.82 | 1.16 | 0.72 | |
EV/Sales |
0.20 | 0.21 | 0.07 | (0.02) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.40 | |
EV/Operating CF |
(1.58) | (1.07) | (0.33) | 0.20 | |
EV/FCF |
(1.47) | (1.01) | (0.31) | 0.19 | |
Quick Ratio |
1.33 | 1.17 | 1.02 | 1.56 | |
Current Ratio |
2.89 | 2.88 | 2.50 | 2.99 | |
Net Debt/EBITDA |
10.08 | 3.98 | 7.54 | 667.25 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.23 | 1.30 | 1.41 | 1.34 | |
Operating CF/Net income |
1.19 | 0.93 | 0.89 | 1.97 | |
Capex/Depreciation |
(0.28) | (1.38) | (0.88) | (0.06) | |
Research and Development Expense of Revenue |
10.26% | 12.81% | 9.80% | 9.32% | |
Selling, General and Administrative Expense of Revenue |
33.58% | 40.72% | 35.73% | 31.53% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.70% | 0.55% | 2.43% | 0.91% | |
Graham Net Nets |
0.38 | 0.31 | 0.34 | 1.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(56.44%) | (56.04%) | (88.73%) | (99.19%) | |
Free Cash Flow Yield |
(36.72%) | (59.64%) | (115.00%) | (56.12%) | |
Revenue per Share |
3.40 | 2.54 | 3.30 | 1.67 | |
Operating CF per Share |
(0.39) | (0.45) | (0.31) | (0.17) | |
Capex per Share |
(0.01) | (0.03) | (0.02) | 0.00 | |
Free Cash Flow per Share |
(0.39) | (0.47) | (0.33) | (0.17) | |
Cash per Share |
1.84 | 1.50 | 1.42 | 1.39 | |
Shareholders Equity per Share |
2.30 | 2.00 | 1.84 | 1.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.30 | 2.00 | 1.84 | 1.71 | |
Free Cash Flow |
(0.64) | (0.81) | (0.55) | (0.65) | |
Working Capital |
8.18 | 7.93 | 7.27 | 10.82 | |
Capital Expenditures |
(0.01) | (0.05) | (0.03) | 0.00 | |
Net Current Asset Value |
2.43 | 1.95 | 1.24 | 4.76 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.36 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.93 | 2.39 | 2.38 | 2.89 | |
Average Payables |
1.09 | 1.52 | 1.44 | 2.12 | |
Average Inventory |
3.24 | 3.42 | 3.28 | 3.79 | |
Average Assets |
13.77 | 13.65 | 13.83 | 16.35 | |
Average Common Equity |
4.57 | 4.15 | 3.75 | 5.33 |
Columns are period end dates